Skip to main content
. 2008 Jul 14;7:20. doi: 10.1186/1475-2891-7-20

Figure 1.

Figure 1

Nasal Symptom Scale scores by allergen challenge dose and treatment. Not all subjects underwent the full dose-response due to maximum possible response before reaching the full dose (6250 AU/ml). The number of subjects tested at 0, 50, 250, 1250, and 6250 AU/ml were respectively 20, 20, 20, 15, and 13 in the Placebo treatment condition; 20, 20, 20, 14, and 13 in the loratadine treatment condition; and 19, 19, 19, 15, and 13 in the CBP treatment condition.